Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy;
Department of Clinical and Experimental Medicine, Division of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.
Anticancer Res. 2023 Apr;43(4):1643-1648. doi: 10.21873/anticanres.16315.
BACKGROUND/AIM: The expression of the cyclin-dependent kinase inhibitor p16 correlates with the presence of human papillomavirus. The purpose of this investigation was to assess the prognostic relevance of p16 expression in patients with vulvar squamous cell carcinoma (VSCC) treated with radical surgery followed by adjuvant (chemo) radiation in selected cases.
Seventy-eight patients were analyzed retrospectively.
Positive p16 immunostaining was detected in 19 (24.4%) patients. Five-year disease-free survival (DFS) and 5-year overall survival (OS) were better in p16-positive compared to p16-negative patients (83.9% versus 37.3% p=0.002 and 91.7% versus 57.6%, p=0.003, respectively). p16 expression retained prognostic relevance at multivariate analysis for both DFS and OS.
p16 expression was detected in 24.4% of patients with VSCC and was found to be an independent prognostic variable for both DFS and OS.
背景/目的：细胞周期蛋白依赖性激酶抑制剂 p16 的表达与人类乳头瘤病毒的存在相关。本研究旨在评估在接受根治性手术加辅助（化疗）放疗的外阴鳞癌（VSCC）患者中，p16 表达的预后相关性，这些患者是经过选择的。
回顾性分析了 78 例患者。
19 例（24.4%）患者的 p16 免疫染色阳性。p16 阳性患者的 5 年无病生存率（DFS）和 5 年总生存率（OS）明显优于 p16 阴性患者（83.9%对 37.3%，p=0.002；91.7%对 57.6%，p=0.003）。在多变量分析中，p16 表达对 DFS 和 OS 均具有预后相关性。
在 VSCC 患者中，检测到 24.4%的患者存在 p16 表达，p16 表达被发现是 DFS 和 OS 的独立预后变量。
